Nuclear lamins, fibrous proteins forming a mesh-like structure underneath the nuclear envelope, are fundamental to maintaining nuclear shape, organizing chromatin, and regulating gene expression. Despite their critical role, the precise molecular regulation of lamins during the cell cycle, particularly mitosis, remains incompletely understood. The new research by Cipressa et al. investigates how separase, a well-characterized protease known primarily for its function in cleaving cohesin complexes to enable sister chromatid separation, also targets nuclear lamins to orchestrate nuclear envelope dynamics.

In their meticulous experiments, the authors utilized a sophisticated combination of molecular biology, cell imaging, and biochemical assays to demonstrate that separase directly cleaves nuclear lamins, resulting in their timely disassembly during mitosis. This cleavage process is essential for nuclear envelope breakdown, a prerequisite for chromosome segregation and successful cell division. Such findings challenge the traditional view of separase’s specificity and expand its functional repertoire beyond chromosomal cohesion.

Delving deeper, the study highlights that this lamin-regulating role of separase is conserved across species, from yeast to humans. This evolutionary conservation underscores the fundamental importance of separase-mediated lamin cleavage in governing nuclear morphology and mitotic progression. The researchers cross-validated this discovery using multiple model systems, confirming that disrupting separase function leads to aberrant nuclear envelope persistence and subsequent mitotic defects.

To elucidate the mechanistic underpinnings, the team mapped the specific sites on lamin proteins susceptible to separase cleavage and characterized the temporal dynamics of this process. Their results show that separase activity peaks precisely at the onset of anaphase, correlating with nuclear envelope breakdown timing. This precise temporal control ensures that lamins are disassembled only when chromosome segregation is primed, safeguarding genomic stability.

Moreover, the implications of these findings transcend basic cell biology, potentially impacting our understanding of diseases linked to lamin disorders, collectively known as laminopathies. Aberrations in lamin processing or structure contribute to a spectrum of pathologies, including muscular dystrophies, cardiomyopathies, and premature aging syndromes. Unraveling the regulatory network involving separase could therefore inform therapeutic strategies aimed at ameliorating nuclear envelope-related diseases.

The methodological innovations in this study deserve special mention. The authors employed live-cell imaging of fluorescently tagged lamins combined with separase activity reporters, providing unprecedented spatiotemporal resolution of the cleavage events. This allowed real-time visualization of nuclear envelope disintegration, linking biochemical cleavage to morphological changes in cells undergoing mitosis.

Furthermore, integrating proteomics screens revealed additional separase substrates within nuclear structural components, hinting at a broader role for separase in nuclear architecture remodeling. Such findings raise provocative questions about whether separase coordinates multiple aspects of nuclear envelope dynamics, potentially influencing chromatin organization, DNA repair processes, and nuclear-cytoplasmic transport.

The study also explored the molecular regulators modulating separase’s access to lamins. The activation of separase is tightly controlled by securin degradation and cyclin-dependent kinases, but its interaction with nuclear lamins involves additional factors that may serve as enhancers or shields, fine-tuning lamin cleavage to cellular cues. This regulatory complexity ensures that nuclear envelope breakdown is tightly synchronized with overall cell cycle progression.

Interestingly, the findings suggest that separase’s lamin-cleaving function may have implications for cancer cell proliferation. Many tumors show altered lamin expression and nuclear morphology, contributing to malignancy and metastasis. Understanding how separase-mediated lamin processing is deregulated in cancer cells could reveal vulnerabilities exploitable for anti-cancer therapies, targeting the unique nuclear dynamics in rapidly dividing tumor cells.

Beyond mitosis, the research hints that separase might contribute to nuclear envelope reassembly post-mitosis by modulating lamin re-polymerization or degradation pathways. Such dual functionality would reflect a sophisticated level of control over nuclear envelope integrity, balancing disassembly and reassembly through the proteolytic activity of a single enzyme.

In summary, Cipressa and colleagues have elucidated a previously unrecognized yet evolutionarily conserved function of separase in nuclear lamin regulation. Their findings forge new conceptual ground in the fields of cell biology and molecular genetics, spotlighting the nuclear envelope as a dynamic, protease-regulated structure essential for cell division. Future research inspired by these insights is likely to unravel further complexities in nuclear organization and its perturbation in disease.

This innovative study exemplifies how revisiting established molecular players through fresh lenses can yield transformative insight, reshaping paradigms and potentially driving new clinical advances. The evolutionary conservation of this mechanism reinforces its biological significance, presenting separase as a multifaceted regulator essential not only for chromosome segregation but also for maintaining nuclear architecture through lamin processing.

As scientists continue to decode the molecular choreography of mitosis, the role of separase in lamin cleavage stands out as a crucial piece of the puzzle, emphasizing the exquisite coordination and precision nature employs to orchestrate life at the cellular level. This work inspires a reinvigorated investigation into nuclear lamina dynamics and positions separase as a promising target for biomedical intervention in lamin-related diseases and cancers.

The research community eagerly anticipates follow-up studies addressing separase’s interactions with other nuclear envelope proteins and the downstream consequences of its proteolytic activity. Understanding these pathways in finer detail will be critical for developing strategies to manipulate nuclear architecture therapeutically, offering hope for treating a variety of pathologies rooted in nuclear envelope dysfunction.

Ultimately, this landmark study not only advances fundamental knowledge of cell cycle regulation and nuclear structure but also opens novel avenues in therapeutic development. By uncovering the intricate relationship between separase and nuclear lamins, Cipressa et al. have added a vital chapter to cell biology, demonstrating once again the power of evolutionary conservation to illuminate essential cellular processes.

Subject of Research: Regulation of nuclear lamins by separase during cell cycle progression.

Article Title: An evolutionarily conserved role for separase in the regulation of nuclear lamins.

Article References:
Cipressa, F., Pennarun, G., Bosso, G. et al. An evolutionarily conserved role for separase in the regulation of nuclear lamins. Cell Death Discov. 11, 475 (2025). https://doi.org/10.1038/s41420-025-02758-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02758-5

Cell division is a tightly regulated process, essential for growth, tissue repair, and homeostasis. At the heart of this process lies the family of D-type cyclins—cyclin D1, D2, and D3—which serve as regulatory subunits activating cyclin-dependent kinases (CDKs). These complexes drive the cell from a quiescent state (G0/G1 phase) toward the DNA synthesis (S) phase, propelling the cell into a division cycle. Dysregulation of these pathways, especially overexpression or stabilization of cyclin D proteins, has been implicated in numerous types of cancer, including breast, lung, and pancreatic tumors.

The ubiquitin-proteasome system (UPS) ensures protein quality control within cells by tagging damaged or unnecessary proteins for degradation. F-box proteins, as part of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex, are responsible for substrate recognition in this process. Among more than 70 known F-box proteins, FBXO32 (also known as Atrogin-1) had been primarily associated with muscle atrophy and cellular stress responses—until now. This study reveals that FBXO32 directly interacts with D-type cyclins, adding a new layer of complexity to how cyclin stability is regulated.

Contrary to the canonical role of F-box proteins in promoting degradation, the team discovered that FBXO32 ubiquitinates D-type cyclins—but rather than earmarking them for destruction, this post-translational modification surprisingly stabilizes these proteins. This non-canonical ubiquitination enhances the persistence of cyclin D molecules in the cell, enabling continuous activation of CDKs and unchecked progression through the cell cycle. This mechanism essentially provides cancer cells with a proliferative advantage, allowing tumors to grow rapidly and evade normal growth checkpoints.

Using a combination of mass spectrometry, co-immunoprecipitation assays, and in vivo models, Li and colleagues meticulously mapped the interaction domains between FBXO32 and cyclin D variants. They identified specific lysine residues on cyclin D proteins that serve as ubiquitination sites, demonstrating that mutating these lysines diminished FBXO32-mediated stabilization. This functional tug-of-war between ubiquitination leading to protein degradation versus stabilization is a paradigm shift in the field, underscoring the multifaceted roles of ubiquitin signaling within cells.

To validate their findings’ clinical relevance, the team examined cancer tissue samples and patient-derived xenografts. FBXO32 expression correlated strongly with elevated cyclin D levels and poor prognoses, particularly in aggressive tumor types. Moreover, silencing FBXO32 in cell lines markedly reduced cyclin D stability, attenuated cell proliferation, and sensitized tumor cells to CDK4/6 inhibitors—highlighting a potential therapeutic vulnerability.

The discovery of FBXO32’s unique function posits the protein as a double-edged sword: while crucial for normal cellular responses under stress, its aberrant activity in cancer cells fuels malignant progression. Such a dual role underscores the need for carefully designed therapeutic strategies that selectively inhibit FBXO32’s oncogenic interaction without perturbing its physiological functions in healthy tissues.

From a broader perspective, this research challenges the simplistic view that ubiquitination universally signals proteins for degradation. Instead, it illuminates how specific ubiquitin linkages and contexts can modulate substrate fate, resulting in stabilization or altered activity. Decoding this ubiquitin “language” is critical for designing next-generation therapeutics that manipulate protein function with unprecedented precision.

The implications of this study extend beyond oncology. Given FBXO32’s expression profile in muscle tissue, neurodegenerative disorders, and immune cells, understanding its ubiquitination mechanisms may inform diverse biomedical fields. The team’s approach—integrating molecular biology, biochemistry, and in vivo analyses—serves as an exemplary model for dissecting complex protein regulatory networks.

Looking ahead, researchers aim to develop small molecules or biologics targeting the FBXO32-cyclin D interaction interface. Such agents could effectively destabilize cyclin D proteins in tumors, halting cell cycle progression and tumor growth. Furthermore, combinatorial treatments pairing FBXO32 inhibitors with existing CDK4/6 inhibitors hold promise for overcoming resistance often encountered in the clinic.

This discovery also accentuates the value of examining “non-canonical” functions of well-characterized protein families. Many F-box proteins likely engage in unanticipated cellular processes, with significant pathological implications. Expanding the investigation of these substrates and their modification patterns may reveal novel regulatory circuits governing cellular homeostasis and disease.

In essence, the study by Li, Yu, Zhang, et al. represents a quantum leap in our understanding of cell cycle regulation in cancer. By unveiling FBXO32’s role in ubiquitinating and stabilizing D-type cyclins, the researchers have revealed a previously unrecognized mechanism driving cancer progression. This insight not only enriches fundamental biology but also paves the way for innovative cancer therapies targeting an Achilles’ heel of proliferative tumors.

As cancer remains a leading cause of death worldwide, such molecular insights are invaluable. They inspire new hope that precision medicine approaches can be refined to disrupt critical oncogenic pathways more effectively, minimize side effects, and improve patient survival globally. The urgency to translate these findings into clinical applications cannot be overstated, as each step forward brings us closer to more effective cancer therapeutics.

In conclusion, the elucidation of FBXO32’s unexpected ubiquitination role redefines how we conceptualize protein stability regulation in cancer biology. This breakthrough prompts a reevaluation of ubiquitin ligase functions and their diverse roles in maintaining cellular equilibrium or, conversely, facilitating disease. The landscape of targeted cancer therapy is poised for transformation thanks to such pioneering research efforts.

Subject of Research: The role of F-box protein FBXO32 in ubiquitinating and stabilizing D-type cyclins to promote cancer progression.

Article Title: F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression.

Article References:
Li, F., Yu, H., Zhang, Y. et al. F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression. Nat Commun 16, 4060 (2025). https://doi.org/10.1038/s41467-025-59407-9

Image Credits: AI Generated